Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma
Tumor casting hydrogels for interventional radiology treatment of hepatocellular carcinoma
批准号:
10397989
负责人:
David Peter Cormode
金额:
$24.38万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-05-01 至 2025-01-31
关键词:
AutophagocytosisBiodistributionBiologyBlood VesselsBlood capillariesBlood flowBody TemperatureCancer EtiologyCessation of lifeCharacteristicsChemicalsChemoembolizationChitosanCirrhosisClinical TrialsContrast MediaCrosslinkerCytotoxic agentDevelopmentDoseDoxorubicinDrug Delivery SystemsDrug usageEmulsionsEncapsulatedEnsureFluoroscopyFormulationFundingGelGenerationsHot SpotHydrogelsImageImaging TechniquesIn VitroIncidenceIndustrializationInjectableInjectionsInterventionInterventional radiologyIronIschemiaKidneyLabelLeadMagnetic Resonance ImagingMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of liverMethodsMicrospheresMonitorNeoplasms in Vascular TissueObstructionPatient-Focused OutcomesPatientsPenetrationPharmaceutical PreparationsPhotonsPolysaccharidesPositioning AttributePrimary carcinoma of the liver cellsProceduresPropertyRattusRecurrent diseaseResearchResidual stateRheologyRoentgen RaysScanningSurvival RateSystemTechnologyTherapeuticTherapeutic EmbolizationTimeToxicologyUnited StatesUnited States National Institutes of HealthUnresectableViscosityVisualizationWorkX-Ray Computed TomographyX-Ray Medical Imaginganti-cancerantitumor effectattenuationbiomaterial compatibilityclinical translationcytotoxicitydrug developmentefficacy studyefficacy testingfeedingimage guidedimprovedimproved outcomein vivoinhibitoriron oxide nanoparticleliver cancer modelliver cancer patientminimally invasivenanoGoldnovelpublic health relevanceradiologistsafety studystandard of caretargeted deliverytargeted treatmenttumortumor vascular supply
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States. One of
the major treatments used for HCC is embolization, i.e. blocking the blood vessels feeding a tumor with
microbeads. Drug-eluting beads (DEBs) are frequently used for this purpose. Despite the development of
DEBs, patient survival rate is only 27% at 5 years. This may be due to poor drug eluting characteristics and
incomplete embolization since the beads are large compared to the size of tumor capillaries. At the same time,
being typically radiolucent, those beads cannot be visualized via imaging, so it is challenging to assess their
successful deployment during the procedure. Therefore, the development of biodegradable materials that can
block blood vessels, have tunable drug release, as well as incorporate materials with radiopaque properties,
would be advantageous. We propose a novel injectable, thermo-sensitive, radiopaque and drug-eluting
hydrogel as a therapeutic platform for HCC treatment, which will completely occlude tumor blood vessels.
Renally clearable gold nanoparticles (AuNP) will be used to render the gel radiopaque since they have strong
X-ray attenuation, excellent biocompatibility and can eventually be excreted. In this proposed research,
AuNP/drug loaded hydrogels will be synthesized and will be physically and chemically characterized. In vivo
studies examining the contrast generating properties of the gel, its anti-tumor effects, its biodistribution and
clearance will be performed. The results of this work will set the stage for the additional efficacy and safety
studies needed prior to clinical translation.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/acsami.2c12354
发表时间:
2022-08-31
期刊:
ACS APPLIED MATERIALS & INTERFACES
影响因子:
9.5
作者:
[Dong, Yuxi C., Kumar, Ananyaa, Rosario-Berrios, Derick N., Si-Mohamed, Salim, Hsu, Jessica C., Nieves, Lenitza M., Douek, Philippe, Noel, Peter B., Cormode, David P.]
通讯作者:
Cormode, David P.
Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography
-
批准号:10459234
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2021
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:9925060
-
项目类别:
-
资助金额:$52.44万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:10392420
-
项目类别:
-
资助金额:$43.94万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Nanoparticle contrast agents for earlier breast cancer detection
-
批准号:9815637
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2018
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable gold nanoparticles as contrast agents for CT
-
批准号:9341531
-
项目类别:
-
资助金额:$22.3万
-
财政年份:2017
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging
-
批准号:9899293
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:David Peter Cormode
-
依托单位:
Biodegradable polymetal nanoparticle CT contrast agents for vascular imaging
-
批准号:9242691
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:David Peter Cormode
-
依托单位:
Macrophage COX-2 as a target in breast cancer chemoprevention
-
批准号:8703435
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2014
-
负责人:David Peter Cormode
-
依托单位:
Macrophage COX-2 as a target in breast cancer chemoprevention
-
批准号:8842600
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2014
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8490376
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8678912
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:7952549
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8120348
-
项目类别:
-
资助金额:$8.94万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
Theranostic Nanoparticles to enhance morpholino delivery to the liver for suppres
-
批准号:8474382
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2010
-
负责人:David Peter Cormode
-
依托单位:
海外基金